Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022
The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late December 2021 (1). BA.1 has since been replaced by emerging lineages BA.2 (including BA.2.12.1) in March 2022, followed by BA.4 and BA.5, which have accounted for a majority of SARS-CoV-2 infections si...
Gespeichert in:
| Veröffentlicht in: | MMWR. Morbidity and mortality weekly report 2022-10, Vol.71 (42), p.1327-1334 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1334 |
|---|---|
| container_issue | 42 |
| container_start_page | 1327 |
| container_title | MMWR. Morbidity and mortality weekly report |
| container_volume | 71 |
| creator | Surie, Diya Bonnell, Levi Adams, Katherine Gaglani, Manjusha Ginde, Adit A Douin, David J Talbot, H Keipp Casey, Jonathan D Mohr, Nicholas M Zepeski, Anne McNeal, Tresa Ghamande, Shekhar Gibbs, Kevin W Files, D Clark Hager, David N Shehu, Arber Frosch, Anne P Erickson, Heidi L Gong, Michelle N Mohamed, Amira Johnson, Nicholas J Srinivasan, Vasisht Steingrub, Jay S Peltan, Ithan D Brown, Samuel M Martin, Emily T Khan, Akram Bender, William S Duggal, Abhijit Wilson, Jennifer G Qadir, Nida Chang, Steven Y Mallow, Christopher Rivas, Carolina Kwon, Jennie H Exline, Matthew C Lauring, Adam S Shapiro, Nathan I Halasa, Natasha Chappell, James D Grijalva, Carlos G Rice, Todd W Stubblefield, William B Baughman, Adrienne Womack, Kelsey N Hart, Kimberly W Swan, Sydney A Zhu, Yuwei DeCuir, Jennifer Tenforde, Mark W Patel, Manish M McMorrow, Meredith L Self, Wesley H |
| description | The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late December 2021 (1). BA.1 has since been replaced by emerging lineages BA.2 (including BA.2.12.1) in March 2022, followed by BA.4 and BA.5, which have accounted for a majority of SARS-CoV-2 infections since late June 2022 (1). Data on the effectiveness of monovalent mRNA COVID-19 vaccines against BA.4/BA.5-associated hospitalizations are limited, and their interpretation is complicated by waning of vaccine-induced immunity (2-5). Further, infections with earlier Omicron lineages, including BA.1 and BA.2, reduce vaccine effectiveness (VE) estimates because certain persons in the referent unvaccinated group have protection from infection-induced immunity. The IVY Network
assessed effectiveness of 2, 3, and 4 doses of monovalent mRNA vaccines compared with no vaccination against COVID-19-associated hospitalization among immunocompetent adults aged ≥18 years during December 26, 2021-August 31, 2022. During the BA.1/BA.2 period, VE 14-150 days after a second dose was 63% and decreased to 34% after 150 days. Similarly, VE 7-120 days after a third dose was 79% and decreased to 41% after 120 days. VE 7-120 days after a fourth dose was 61%. During the BA.4/BA.5 period, similar trends were observed, although CIs for VE estimates between categories of time since the last dose overlapped. VE 14-150 days and >150 days after a second dose was 83% and 37%, respectively. VE 7-120 days and >120 days after a third dose was 60%and 29%, respectively. VE 7-120 days after the fourth dose was 61%. Protection against COVID-19-associated hospitalization waned even after a third dose. The newly authorized bivalent COVID-19 vaccines include mRNA from the ancestral SARS-CoV-2 strain and from shared mRNA components between BA.4 and BA.5 lineages and are expected to be more immunogenic against BA.4/BA.5 than monovalent mRNA COVID-19 vaccines (6-8). All eligible adults aged ≥18 years
should receive a booster dose, which currently consists of a bivalent mRNA vaccine, to maximize protection against BA.4/BA.5 and prevent COVID-19-associated hospitalization. |
| doi_str_mv | 10.15585/mmwr.mm7142a3 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9590291</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A724886540</galeid><sourcerecordid>A724886540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c619t-ec07ef57160624016ac0b0c93132ea7d42dc8e117a5e55463a492f0a7534f9943</originalsourceid><addsrcrecordid>eNptk01v1DAQhgMC0VK4IY7IAglxaLa2Y-fjghS2ha5U2qqlKzhFrjPZNcT2Yjut4Nfj9Est2liKNZlnXo8nM0nymuAJ4bzkO1pfuonWBWFUZI-TTcIZT8ucfH-SbGLCqpSSim8kz73_iccnw8-SjSynOSszvPno1V7XgQzqAgx4j2yHvlpjL0QPJiB9clijuZBSRSeqF0IZH9D0aD7bTUmV1t5bqUSAFu1bv1JB9OqvCMoaVGtrFmim9WCstHoFYdSr26EPHu0OTkXvp3pCduKLImHa0WKjxdGxg9ZqZUSMOAanbHuV12l9cppO7Tyl6Egr6eIpc-HUSCmDwhLQmVFjLqchpuRRimbzH-gQwqV1v7YRKW8c22gXJOhzcIjm24hiStJ6WAzxZhm5sumL5Gkneg8vb_at5Ozz3rfpfnpw9GU2rQ9SmZMqpCBxAR0vSI5zyjDJhcTnWFYZySiIomW0lSUQUggOnLM8E6yiHRYFz1hXVSzbSj5e666Gcw2tjDVyom9WTmnh_jRWqOahx6hls7AXTcUrTCsSBd7eCDj7ewAfGgcr64JvaMFzQnlFR-jDf5BWXkLfCwN2GFFa5IzlZETfXaOL2ACNMp2Nx8oRb-qCsrLMOcORStdQi9hBMUdroFPx8wN-soaPq4X4I9cGvL8XsATRh6W3_TC2ll-rHNvBewfdXe0Ibq7moxnno7mdjxjw5n7F7_Dbgcj-Ac79BpI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2756125921</pqid></control><display><type>article</type><title>Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Surie, Diya ; Bonnell, Levi ; Adams, Katherine ; Gaglani, Manjusha ; Ginde, Adit A ; Douin, David J ; Talbot, H Keipp ; Casey, Jonathan D ; Mohr, Nicholas M ; Zepeski, Anne ; McNeal, Tresa ; Ghamande, Shekhar ; Gibbs, Kevin W ; Files, D Clark ; Hager, David N ; Shehu, Arber ; Frosch, Anne P ; Erickson, Heidi L ; Gong, Michelle N ; Mohamed, Amira ; Johnson, Nicholas J ; Srinivasan, Vasisht ; Steingrub, Jay S ; Peltan, Ithan D ; Brown, Samuel M ; Martin, Emily T ; Khan, Akram ; Bender, William S ; Duggal, Abhijit ; Wilson, Jennifer G ; Qadir, Nida ; Chang, Steven Y ; Mallow, Christopher ; Rivas, Carolina ; Kwon, Jennie H ; Exline, Matthew C ; Lauring, Adam S ; Shapiro, Nathan I ; Halasa, Natasha ; Chappell, James D ; Grijalva, Carlos G ; Rice, Todd W ; Stubblefield, William B ; Baughman, Adrienne ; Womack, Kelsey N ; Hart, Kimberly W ; Swan, Sydney A ; Zhu, Yuwei ; DeCuir, Jennifer ; Tenforde, Mark W ; Patel, Manish M ; McMorrow, Meredith L ; Self, Wesley H</creator><creatorcontrib>Surie, Diya ; Bonnell, Levi ; Adams, Katherine ; Gaglani, Manjusha ; Ginde, Adit A ; Douin, David J ; Talbot, H Keipp ; Casey, Jonathan D ; Mohr, Nicholas M ; Zepeski, Anne ; McNeal, Tresa ; Ghamande, Shekhar ; Gibbs, Kevin W ; Files, D Clark ; Hager, David N ; Shehu, Arber ; Frosch, Anne P ; Erickson, Heidi L ; Gong, Michelle N ; Mohamed, Amira ; Johnson, Nicholas J ; Srinivasan, Vasisht ; Steingrub, Jay S ; Peltan, Ithan D ; Brown, Samuel M ; Martin, Emily T ; Khan, Akram ; Bender, William S ; Duggal, Abhijit ; Wilson, Jennifer G ; Qadir, Nida ; Chang, Steven Y ; Mallow, Christopher ; Rivas, Carolina ; Kwon, Jennie H ; Exline, Matthew C ; Lauring, Adam S ; Shapiro, Nathan I ; Halasa, Natasha ; Chappell, James D ; Grijalva, Carlos G ; Rice, Todd W ; Stubblefield, William B ; Baughman, Adrienne ; Womack, Kelsey N ; Hart, Kimberly W ; Swan, Sydney A ; Zhu, Yuwei ; DeCuir, Jennifer ; Tenforde, Mark W ; Patel, Manish M ; McMorrow, Meredith L ; Self, Wesley H ; IVY Network</creatorcontrib><description>The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late December 2021 (1). BA.1 has since been replaced by emerging lineages BA.2 (including BA.2.12.1) in March 2022, followed by BA.4 and BA.5, which have accounted for a majority of SARS-CoV-2 infections since late June 2022 (1). Data on the effectiveness of monovalent mRNA COVID-19 vaccines against BA.4/BA.5-associated hospitalizations are limited, and their interpretation is complicated by waning of vaccine-induced immunity (2-5). Further, infections with earlier Omicron lineages, including BA.1 and BA.2, reduce vaccine effectiveness (VE) estimates because certain persons in the referent unvaccinated group have protection from infection-induced immunity. The IVY Network
assessed effectiveness of 2, 3, and 4 doses of monovalent mRNA vaccines compared with no vaccination against COVID-19-associated hospitalization among immunocompetent adults aged ≥18 years during December 26, 2021-August 31, 2022. During the BA.1/BA.2 period, VE 14-150 days after a second dose was 63% and decreased to 34% after 150 days. Similarly, VE 7-120 days after a third dose was 79% and decreased to 41% after 120 days. VE 7-120 days after a fourth dose was 61%. During the BA.4/BA.5 period, similar trends were observed, although CIs for VE estimates between categories of time since the last dose overlapped. VE 14-150 days and >150 days after a second dose was 83% and 37%, respectively. VE 7-120 days and >120 days after a third dose was 60%and 29%, respectively. VE 7-120 days after the fourth dose was 61%. Protection against COVID-19-associated hospitalization waned even after a third dose. The newly authorized bivalent COVID-19 vaccines include mRNA from the ancestral SARS-CoV-2 strain and from shared mRNA components between BA.4 and BA.5 lineages and are expected to be more immunogenic against BA.4/BA.5 than monovalent mRNA COVID-19 vaccines (6-8). All eligible adults aged ≥18 years
should receive a booster dose, which currently consists of a bivalent mRNA vaccine, to maximize protection against BA.4/BA.5 and prevent COVID-19-associated hospitalization.</description><identifier>ISSN: 0149-2195</identifier><identifier>EISSN: 1545-861X</identifier><identifier>DOI: 10.15585/mmwr.mm7142a3</identifier><identifier>PMID: 36264830</identifier><language>eng</language><publisher>United States: U.S. Government Printing Office</publisher><subject>Adolescent ; Adult ; Adults ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Effectiveness ; Full Report ; Health aspects ; Hispanic Americans ; Hospitalization ; Humans ; Illnesses ; Immunocompetence ; Infection ; Medical research ; Medicine, Experimental ; Messenger RNA ; mRNA ; mRNA Vaccines ; Pharmaceutical industry ; Public health ; RNA, Messenger ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Trends ; United States - epidemiology ; Vaccine efficacy ; Vaccines ; Vaccines, Combined</subject><ispartof>MMWR. Morbidity and mortality weekly report, 2022-10, Vol.71 (42), p.1327-1334</ispartof><rights>COPYRIGHT 2022 U.S. Government Printing Office</rights><rights>Published 2022. This article is a U.S. Government work and is in the public domain in the USA.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c619t-ec07ef57160624016ac0b0c93132ea7d42dc8e117a5e55463a492f0a7534f9943</citedby><cites>FETCH-LOGICAL-c619t-ec07ef57160624016ac0b0c93132ea7d42dc8e117a5e55463a492f0a7534f9943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590291/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590291/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36264830$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Surie, Diya</creatorcontrib><creatorcontrib>Bonnell, Levi</creatorcontrib><creatorcontrib>Adams, Katherine</creatorcontrib><creatorcontrib>Gaglani, Manjusha</creatorcontrib><creatorcontrib>Ginde, Adit A</creatorcontrib><creatorcontrib>Douin, David J</creatorcontrib><creatorcontrib>Talbot, H Keipp</creatorcontrib><creatorcontrib>Casey, Jonathan D</creatorcontrib><creatorcontrib>Mohr, Nicholas M</creatorcontrib><creatorcontrib>Zepeski, Anne</creatorcontrib><creatorcontrib>McNeal, Tresa</creatorcontrib><creatorcontrib>Ghamande, Shekhar</creatorcontrib><creatorcontrib>Gibbs, Kevin W</creatorcontrib><creatorcontrib>Files, D Clark</creatorcontrib><creatorcontrib>Hager, David N</creatorcontrib><creatorcontrib>Shehu, Arber</creatorcontrib><creatorcontrib>Frosch, Anne P</creatorcontrib><creatorcontrib>Erickson, Heidi L</creatorcontrib><creatorcontrib>Gong, Michelle N</creatorcontrib><creatorcontrib>Mohamed, Amira</creatorcontrib><creatorcontrib>Johnson, Nicholas J</creatorcontrib><creatorcontrib>Srinivasan, Vasisht</creatorcontrib><creatorcontrib>Steingrub, Jay S</creatorcontrib><creatorcontrib>Peltan, Ithan D</creatorcontrib><creatorcontrib>Brown, Samuel M</creatorcontrib><creatorcontrib>Martin, Emily T</creatorcontrib><creatorcontrib>Khan, Akram</creatorcontrib><creatorcontrib>Bender, William S</creatorcontrib><creatorcontrib>Duggal, Abhijit</creatorcontrib><creatorcontrib>Wilson, Jennifer G</creatorcontrib><creatorcontrib>Qadir, Nida</creatorcontrib><creatorcontrib>Chang, Steven Y</creatorcontrib><creatorcontrib>Mallow, Christopher</creatorcontrib><creatorcontrib>Rivas, Carolina</creatorcontrib><creatorcontrib>Kwon, Jennie H</creatorcontrib><creatorcontrib>Exline, Matthew C</creatorcontrib><creatorcontrib>Lauring, Adam S</creatorcontrib><creatorcontrib>Shapiro, Nathan I</creatorcontrib><creatorcontrib>Halasa, Natasha</creatorcontrib><creatorcontrib>Chappell, James D</creatorcontrib><creatorcontrib>Grijalva, Carlos G</creatorcontrib><creatorcontrib>Rice, Todd W</creatorcontrib><creatorcontrib>Stubblefield, William B</creatorcontrib><creatorcontrib>Baughman, Adrienne</creatorcontrib><creatorcontrib>Womack, Kelsey N</creatorcontrib><creatorcontrib>Hart, Kimberly W</creatorcontrib><creatorcontrib>Swan, Sydney A</creatorcontrib><creatorcontrib>Zhu, Yuwei</creatorcontrib><creatorcontrib>DeCuir, Jennifer</creatorcontrib><creatorcontrib>Tenforde, Mark W</creatorcontrib><creatorcontrib>Patel, Manish M</creatorcontrib><creatorcontrib>McMorrow, Meredith L</creatorcontrib><creatorcontrib>Self, Wesley H</creatorcontrib><creatorcontrib>IVY Network</creatorcontrib><title>Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022</title><title>MMWR. Morbidity and mortality weekly report</title><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><description>The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late December 2021 (1). BA.1 has since been replaced by emerging lineages BA.2 (including BA.2.12.1) in March 2022, followed by BA.4 and BA.5, which have accounted for a majority of SARS-CoV-2 infections since late June 2022 (1). Data on the effectiveness of monovalent mRNA COVID-19 vaccines against BA.4/BA.5-associated hospitalizations are limited, and their interpretation is complicated by waning of vaccine-induced immunity (2-5). Further, infections with earlier Omicron lineages, including BA.1 and BA.2, reduce vaccine effectiveness (VE) estimates because certain persons in the referent unvaccinated group have protection from infection-induced immunity. The IVY Network
assessed effectiveness of 2, 3, and 4 doses of monovalent mRNA vaccines compared with no vaccination against COVID-19-associated hospitalization among immunocompetent adults aged ≥18 years during December 26, 2021-August 31, 2022. During the BA.1/BA.2 period, VE 14-150 days after a second dose was 63% and decreased to 34% after 150 days. Similarly, VE 7-120 days after a third dose was 79% and decreased to 41% after 120 days. VE 7-120 days after a fourth dose was 61%. During the BA.4/BA.5 period, similar trends were observed, although CIs for VE estimates between categories of time since the last dose overlapped. VE 14-150 days and >150 days after a second dose was 83% and 37%, respectively. VE 7-120 days and >120 days after a third dose was 60%and 29%, respectively. VE 7-120 days after the fourth dose was 61%. Protection against COVID-19-associated hospitalization waned even after a third dose. The newly authorized bivalent COVID-19 vaccines include mRNA from the ancestral SARS-CoV-2 strain and from shared mRNA components between BA.4 and BA.5 lineages and are expected to be more immunogenic against BA.4/BA.5 than monovalent mRNA COVID-19 vaccines (6-8). All eligible adults aged ≥18 years
should receive a booster dose, which currently consists of a bivalent mRNA vaccine, to maximize protection against BA.4/BA.5 and prevent COVID-19-associated hospitalization.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adults</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Effectiveness</subject><subject>Full Report</subject><subject>Health aspects</subject><subject>Hispanic Americans</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Immunocompetence</subject><subject>Infection</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Messenger RNA</subject><subject>mRNA</subject><subject>mRNA Vaccines</subject><subject>Pharmaceutical industry</subject><subject>Public health</subject><subject>RNA, Messenger</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Trends</subject><subject>United States - epidemiology</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Vaccines, Combined</subject><issn>0149-2195</issn><issn>1545-861X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptk01v1DAQhgMC0VK4IY7IAglxaLa2Y-fjghS2ha5U2qqlKzhFrjPZNcT2Yjut4Nfj9Est2liKNZlnXo8nM0nymuAJ4bzkO1pfuonWBWFUZI-TTcIZT8ucfH-SbGLCqpSSim8kz73_iccnw8-SjSynOSszvPno1V7XgQzqAgx4j2yHvlpjL0QPJiB9clijuZBSRSeqF0IZH9D0aD7bTUmV1t5bqUSAFu1bv1JB9OqvCMoaVGtrFmim9WCstHoFYdSr26EPHu0OTkXvp3pCduKLImHa0WKjxdGxg9ZqZUSMOAanbHuV12l9cppO7Tyl6Egr6eIpc-HUSCmDwhLQmVFjLqchpuRRimbzH-gQwqV1v7YRKW8c22gXJOhzcIjm24hiStJ6WAzxZhm5sumL5Gkneg8vb_at5Ozz3rfpfnpw9GU2rQ9SmZMqpCBxAR0vSI5zyjDJhcTnWFYZySiIomW0lSUQUggOnLM8E6yiHRYFz1hXVSzbSj5e666Gcw2tjDVyom9WTmnh_jRWqOahx6hls7AXTcUrTCsSBd7eCDj7ewAfGgcr64JvaMFzQnlFR-jDf5BWXkLfCwN2GFFa5IzlZETfXaOL2ACNMp2Nx8oRb-qCsrLMOcORStdQi9hBMUdroFPx8wN-soaPq4X4I9cGvL8XsATRh6W3_TC2ll-rHNvBewfdXe0Ibq7moxnno7mdjxjw5n7F7_Dbgcj-Ac79BpI</recordid><startdate>20221021</startdate><enddate>20221021</enddate><creator>Surie, Diya</creator><creator>Bonnell, Levi</creator><creator>Adams, Katherine</creator><creator>Gaglani, Manjusha</creator><creator>Ginde, Adit A</creator><creator>Douin, David J</creator><creator>Talbot, H Keipp</creator><creator>Casey, Jonathan D</creator><creator>Mohr, Nicholas M</creator><creator>Zepeski, Anne</creator><creator>McNeal, Tresa</creator><creator>Ghamande, Shekhar</creator><creator>Gibbs, Kevin W</creator><creator>Files, D Clark</creator><creator>Hager, David N</creator><creator>Shehu, Arber</creator><creator>Frosch, Anne P</creator><creator>Erickson, Heidi L</creator><creator>Gong, Michelle N</creator><creator>Mohamed, Amira</creator><creator>Johnson, Nicholas J</creator><creator>Srinivasan, Vasisht</creator><creator>Steingrub, Jay S</creator><creator>Peltan, Ithan D</creator><creator>Brown, Samuel M</creator><creator>Martin, Emily T</creator><creator>Khan, Akram</creator><creator>Bender, William S</creator><creator>Duggal, Abhijit</creator><creator>Wilson, Jennifer G</creator><creator>Qadir, Nida</creator><creator>Chang, Steven Y</creator><creator>Mallow, Christopher</creator><creator>Rivas, Carolina</creator><creator>Kwon, Jennie H</creator><creator>Exline, Matthew C</creator><creator>Lauring, Adam S</creator><creator>Shapiro, Nathan I</creator><creator>Halasa, Natasha</creator><creator>Chappell, James D</creator><creator>Grijalva, Carlos G</creator><creator>Rice, Todd W</creator><creator>Stubblefield, William B</creator><creator>Baughman, Adrienne</creator><creator>Womack, Kelsey N</creator><creator>Hart, Kimberly W</creator><creator>Swan, Sydney A</creator><creator>Zhu, Yuwei</creator><creator>DeCuir, Jennifer</creator><creator>Tenforde, Mark W</creator><creator>Patel, Manish M</creator><creator>McMorrow, Meredith L</creator><creator>Self, Wesley H</creator><general>U.S. Government Printing Office</general><general>U.S. Center for Disease Control</general><general>Centers for Disease Control and Prevention</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>0-V</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>88F</scope><scope>88J</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M1Q</scope><scope>M2O</scope><scope>M2R</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>S0X</scope><scope>5PM</scope></search><sort><creationdate>20221021</creationdate><title>Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022</title><author>Surie, Diya ; Bonnell, Levi ; Adams, Katherine ; Gaglani, Manjusha ; Ginde, Adit A ; Douin, David J ; Talbot, H Keipp ; Casey, Jonathan D ; Mohr, Nicholas M ; Zepeski, Anne ; McNeal, Tresa ; Ghamande, Shekhar ; Gibbs, Kevin W ; Files, D Clark ; Hager, David N ; Shehu, Arber ; Frosch, Anne P ; Erickson, Heidi L ; Gong, Michelle N ; Mohamed, Amira ; Johnson, Nicholas J ; Srinivasan, Vasisht ; Steingrub, Jay S ; Peltan, Ithan D ; Brown, Samuel M ; Martin, Emily T ; Khan, Akram ; Bender, William S ; Duggal, Abhijit ; Wilson, Jennifer G ; Qadir, Nida ; Chang, Steven Y ; Mallow, Christopher ; Rivas, Carolina ; Kwon, Jennie H ; Exline, Matthew C ; Lauring, Adam S ; Shapiro, Nathan I ; Halasa, Natasha ; Chappell, James D ; Grijalva, Carlos G ; Rice, Todd W ; Stubblefield, William B ; Baughman, Adrienne ; Womack, Kelsey N ; Hart, Kimberly W ; Swan, Sydney A ; Zhu, Yuwei ; DeCuir, Jennifer ; Tenforde, Mark W ; Patel, Manish M ; McMorrow, Meredith L ; Self, Wesley H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c619t-ec07ef57160624016ac0b0c93132ea7d42dc8e117a5e55463a492f0a7534f9943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adults</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Effectiveness</topic><topic>Full Report</topic><topic>Health aspects</topic><topic>Hispanic Americans</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Immunocompetence</topic><topic>Infection</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Messenger RNA</topic><topic>mRNA</topic><topic>mRNA Vaccines</topic><topic>Pharmaceutical industry</topic><topic>Public health</topic><topic>RNA, Messenger</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Trends</topic><topic>United States - epidemiology</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Vaccines, Combined</topic><toplevel>online_resources</toplevel><creatorcontrib>Surie, Diya</creatorcontrib><creatorcontrib>Bonnell, Levi</creatorcontrib><creatorcontrib>Adams, Katherine</creatorcontrib><creatorcontrib>Gaglani, Manjusha</creatorcontrib><creatorcontrib>Ginde, Adit A</creatorcontrib><creatorcontrib>Douin, David J</creatorcontrib><creatorcontrib>Talbot, H Keipp</creatorcontrib><creatorcontrib>Casey, Jonathan D</creatorcontrib><creatorcontrib>Mohr, Nicholas M</creatorcontrib><creatorcontrib>Zepeski, Anne</creatorcontrib><creatorcontrib>McNeal, Tresa</creatorcontrib><creatorcontrib>Ghamande, Shekhar</creatorcontrib><creatorcontrib>Gibbs, Kevin W</creatorcontrib><creatorcontrib>Files, D Clark</creatorcontrib><creatorcontrib>Hager, David N</creatorcontrib><creatorcontrib>Shehu, Arber</creatorcontrib><creatorcontrib>Frosch, Anne P</creatorcontrib><creatorcontrib>Erickson, Heidi L</creatorcontrib><creatorcontrib>Gong, Michelle N</creatorcontrib><creatorcontrib>Mohamed, Amira</creatorcontrib><creatorcontrib>Johnson, Nicholas J</creatorcontrib><creatorcontrib>Srinivasan, Vasisht</creatorcontrib><creatorcontrib>Steingrub, Jay S</creatorcontrib><creatorcontrib>Peltan, Ithan D</creatorcontrib><creatorcontrib>Brown, Samuel M</creatorcontrib><creatorcontrib>Martin, Emily T</creatorcontrib><creatorcontrib>Khan, Akram</creatorcontrib><creatorcontrib>Bender, William S</creatorcontrib><creatorcontrib>Duggal, Abhijit</creatorcontrib><creatorcontrib>Wilson, Jennifer G</creatorcontrib><creatorcontrib>Qadir, Nida</creatorcontrib><creatorcontrib>Chang, Steven Y</creatorcontrib><creatorcontrib>Mallow, Christopher</creatorcontrib><creatorcontrib>Rivas, Carolina</creatorcontrib><creatorcontrib>Kwon, Jennie H</creatorcontrib><creatorcontrib>Exline, Matthew C</creatorcontrib><creatorcontrib>Lauring, Adam S</creatorcontrib><creatorcontrib>Shapiro, Nathan I</creatorcontrib><creatorcontrib>Halasa, Natasha</creatorcontrib><creatorcontrib>Chappell, James D</creatorcontrib><creatorcontrib>Grijalva, Carlos G</creatorcontrib><creatorcontrib>Rice, Todd W</creatorcontrib><creatorcontrib>Stubblefield, William B</creatorcontrib><creatorcontrib>Baughman, Adrienne</creatorcontrib><creatorcontrib>Womack, Kelsey N</creatorcontrib><creatorcontrib>Hart, Kimberly W</creatorcontrib><creatorcontrib>Swan, Sydney A</creatorcontrib><creatorcontrib>Zhu, Yuwei</creatorcontrib><creatorcontrib>DeCuir, Jennifer</creatorcontrib><creatorcontrib>Tenforde, Mark W</creatorcontrib><creatorcontrib>Patel, Manish M</creatorcontrib><creatorcontrib>McMorrow, Meredith L</creatorcontrib><creatorcontrib>Self, Wesley H</creatorcontrib><creatorcontrib>IVY Network</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Military Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Military Database</collection><collection>Research Library</collection><collection>Social Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>MMWR. Morbidity and mortality weekly report</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Surie, Diya</au><au>Bonnell, Levi</au><au>Adams, Katherine</au><au>Gaglani, Manjusha</au><au>Ginde, Adit A</au><au>Douin, David J</au><au>Talbot, H Keipp</au><au>Casey, Jonathan D</au><au>Mohr, Nicholas M</au><au>Zepeski, Anne</au><au>McNeal, Tresa</au><au>Ghamande, Shekhar</au><au>Gibbs, Kevin W</au><au>Files, D Clark</au><au>Hager, David N</au><au>Shehu, Arber</au><au>Frosch, Anne P</au><au>Erickson, Heidi L</au><au>Gong, Michelle N</au><au>Mohamed, Amira</au><au>Johnson, Nicholas J</au><au>Srinivasan, Vasisht</au><au>Steingrub, Jay S</au><au>Peltan, Ithan D</au><au>Brown, Samuel M</au><au>Martin, Emily T</au><au>Khan, Akram</au><au>Bender, William S</au><au>Duggal, Abhijit</au><au>Wilson, Jennifer G</au><au>Qadir, Nida</au><au>Chang, Steven Y</au><au>Mallow, Christopher</au><au>Rivas, Carolina</au><au>Kwon, Jennie H</au><au>Exline, Matthew C</au><au>Lauring, Adam S</au><au>Shapiro, Nathan I</au><au>Halasa, Natasha</au><au>Chappell, James D</au><au>Grijalva, Carlos G</au><au>Rice, Todd W</au><au>Stubblefield, William B</au><au>Baughman, Adrienne</au><au>Womack, Kelsey N</au><au>Hart, Kimberly W</au><au>Swan, Sydney A</au><au>Zhu, Yuwei</au><au>DeCuir, Jennifer</au><au>Tenforde, Mark W</au><au>Patel, Manish M</au><au>McMorrow, Meredith L</au><au>Self, Wesley H</au><aucorp>IVY Network</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022</atitle><jtitle>MMWR. Morbidity and mortality weekly report</jtitle><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><date>2022-10-21</date><risdate>2022</risdate><volume>71</volume><issue>42</issue><spage>1327</spage><epage>1334</epage><pages>1327-1334</pages><issn>0149-2195</issn><eissn>1545-861X</eissn><abstract>The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late December 2021 (1). BA.1 has since been replaced by emerging lineages BA.2 (including BA.2.12.1) in March 2022, followed by BA.4 and BA.5, which have accounted for a majority of SARS-CoV-2 infections since late June 2022 (1). Data on the effectiveness of monovalent mRNA COVID-19 vaccines against BA.4/BA.5-associated hospitalizations are limited, and their interpretation is complicated by waning of vaccine-induced immunity (2-5). Further, infections with earlier Omicron lineages, including BA.1 and BA.2, reduce vaccine effectiveness (VE) estimates because certain persons in the referent unvaccinated group have protection from infection-induced immunity. The IVY Network
assessed effectiveness of 2, 3, and 4 doses of monovalent mRNA vaccines compared with no vaccination against COVID-19-associated hospitalization among immunocompetent adults aged ≥18 years during December 26, 2021-August 31, 2022. During the BA.1/BA.2 period, VE 14-150 days after a second dose was 63% and decreased to 34% after 150 days. Similarly, VE 7-120 days after a third dose was 79% and decreased to 41% after 120 days. VE 7-120 days after a fourth dose was 61%. During the BA.4/BA.5 period, similar trends were observed, although CIs for VE estimates between categories of time since the last dose overlapped. VE 14-150 days and >150 days after a second dose was 83% and 37%, respectively. VE 7-120 days and >120 days after a third dose was 60%and 29%, respectively. VE 7-120 days after the fourth dose was 61%. Protection against COVID-19-associated hospitalization waned even after a third dose. The newly authorized bivalent COVID-19 vaccines include mRNA from the ancestral SARS-CoV-2 strain and from shared mRNA components between BA.4 and BA.5 lineages and are expected to be more immunogenic against BA.4/BA.5 than monovalent mRNA COVID-19 vaccines (6-8). All eligible adults aged ≥18 years
should receive a booster dose, which currently consists of a bivalent mRNA vaccine, to maximize protection against BA.4/BA.5 and prevent COVID-19-associated hospitalization.</abstract><cop>United States</cop><pub>U.S. Government Printing Office</pub><pmid>36264830</pmid><doi>10.15585/mmwr.mm7142a3</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-2195 |
| ispartof | MMWR. Morbidity and mortality weekly report, 2022-10, Vol.71 (42), p.1327-1334 |
| issn | 0149-2195 1545-861X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9590291 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Adolescent Adult Adults Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 Vaccines Effectiveness Full Report Health aspects Hispanic Americans Hospitalization Humans Illnesses Immunocompetence Infection Medical research Medicine, Experimental Messenger RNA mRNA mRNA Vaccines Pharmaceutical industry Public health RNA, Messenger SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Trends United States - epidemiology Vaccine efficacy Vaccines Vaccines, Combined |
| title | Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T14%3A50%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20Monovalent%20mRNA%20Vaccines%20Against%20COVID-19-Associated%20Hospitalization%20Among%20Immunocompetent%20Adults%20During%20BA.1/BA.2%20and%20BA.4/BA.5%20Predominant%20Periods%20of%20SARS-CoV-2%20Omicron%20Variant%20in%20the%20United%20States%20-%20IVY%20Network,%2018%20States,%20December%2026,%202021-August%2031,%202022&rft.jtitle=MMWR.%20Morbidity%20and%20mortality%20weekly%20report&rft.au=Surie,%20Diya&rft.aucorp=IVY%20Network&rft.date=2022-10-21&rft.volume=71&rft.issue=42&rft.spage=1327&rft.epage=1334&rft.pages=1327-1334&rft.issn=0149-2195&rft.eissn=1545-861X&rft_id=info:doi/10.15585/mmwr.mm7142a3&rft_dat=%3Cgale_pubme%3EA724886540%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2756125921&rft_id=info:pmid/36264830&rft_galeid=A724886540&rfr_iscdi=true |